Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	257.84	273.74	99.7	142.14	133.54
Short-Term Investments	153.76	-	-	-	-
Cash & Short-Term Investments	411.59	273.74	99.7	142.14	133.54
Cash Growth	50.36%	174.55%	-29.86%	6.44%	66.73%
Other Current Assets	7.73	7.88	4.17	3.91	3.68
Total Current Assets	419.32	281.62	103.87	146.06	137.22
Other Intangible Assets	-	-	0.53	3.69	6.87
Goodwill	19.92	19.92	19.92	19.92	19.92
Other Long-Term Assets	0.86	0.61	0.22	0.33	-
Total Assets	440.1	302.15	124.54	169.99	164
Accounts Payable	5.35	2.01	4.14	2.11	4.18
Accrued Expenses	20.45	12.83	11.63	5.88	6.23
Other Current Liabilities	40.91	24.01	16.48	9.9	-
Total Current Liabilities	66.7	38.85	32.25	17.89	10.41
Long-Term Debt	40.58	21.85	14.13	-	-
Other Long-Term Liabilities	0.5	-	0.03	1.18	1.93
Total Long-Term Liabilities	41.08	21.85	14.16	1.18	1.93
Total Liabilities	107.77	60.7	46.41	19.08	12.34
Additional Paid-in Capital	913.91	639.51	367.99	344.76	288.29
Accumulated Other Comprehensive Income	1.09	0.82	0.34	0.63	1.05
Retained Earnings	-582.67	-398.88	-290.2	-194.47	-137.67
Shareholders' Equity	332.33	241.45	78.13	150.92	151.66
Total Liabilities & Equity	440.1	302.15	124.54	169.99	164
Total Debt	40.58	21.85	14.13	0	0
Net Cash (Debt)	371.01	251.89	85.58	142.14	133.54
Net Cash Growth	47.29%	194.35%	-39.80%	6.44%	66.73%
Net Cash Per Share	4.15	3.58	2.19	5.01	4.88
Book Value	332.33	241.45	78.13	150.92	151.66
Book Value Per Share	3.72	3.43	2.00	5.32	5.54
Tangible Book Value	312.41	221.53	57.69	127.31	124.88
Tangible Book Value Per Share	3.50	3.14	1.47	4.49	4.56

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.